However, a phase 3 study (PINNACLE) comparing poziotinib versus (vs) docetaxel in pretreated HER2 MUT (Ex20) NSCLC was prematurely withdrawn due to the company’s decision not to fund the study, likely because the safety results from the early-phase trials were not convincing, despite the promising emerging activity [79]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.